Veru Inc (NASDAQ:VERU) CEO Mitchell Shuster Steiner sold 25,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $2.01, for a total value of $50,250.00.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Mitchell Shuster Steiner also recently made the following trade(s):
- On Friday, October 11th, Mitchell Shuster Steiner sold 15,836 shares of Veru stock. The shares were sold at an average price of $2.12, for a total value of $33,572.32.
- On Friday, October 4th, Mitchell Shuster Steiner sold 14,164 shares of Veru stock. The shares were sold at an average price of $2.11, for a total value of $29,886.04.
- On Friday, September 6th, Mitchell Shuster Steiner sold 30,000 shares of Veru stock. The shares were sold at an average price of $1.93, for a total value of $57,900.00.
Shares of Veru stock traded up $0.03 during midday trading on Friday, hitting $2.01. The company had a trading volume of 118,800 shares, compared to its average volume of 155,400. The business’s 50 day simple moving average is $2.05 and its two-hundred day simple moving average is $1.97. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.47 and a quick ratio of 1.20. Veru Inc has a 1-year low of $1.18 and a 1-year high of $2.49. The stock has a market cap of $131.38 million, a PE ratio of -5.15 and a beta of 0.33.
Veru (NASDAQ:VERU) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.04) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). The firm had revenue of $9.73 million during the quarter, compared to analysts’ expectations of $8.11 million. Veru had a negative return on equity of 50.14% and a negative net margin of 59.68%. On average, sell-side analysts expect that Veru Inc will post -0.18 EPS for the current fiscal year.
Several equities analysts have commented on the company. Zacks Investment Research downgraded Veru from a “hold” rating to a “sell” rating in a report on Saturday, October 12th. Brookline Capital Management assumed coverage on Veru in a report on Monday, July 29th. They set a “buy” rating and a $12.00 price target on the stock. HC Wainwright reiterated a “buy” rating on shares of Veru in a report on Thursday, October 3rd. Finally, ValuEngine upgraded Veru from a “sell” rating to a “hold” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. Veru currently has an average rating of “Buy” and an average target price of $5.71.
A number of large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC bought a new stake in Veru during the 3rd quarter worth about $25,000. Perceptive Advisors LLC raised its holdings in Veru by 1.4% during the 2nd quarter. Perceptive Advisors LLC now owns 1,445,000 shares of the company’s stock worth $3,078,000 after purchasing an additional 20,000 shares during the last quarter. BlackRock Inc. raised its holdings in Veru by 65.4% during the 2nd quarter. BlackRock Inc. now owns 228,934 shares of the company’s stock worth $487,000 after purchasing an additional 90,530 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Veru by 183.1% during the 2nd quarter. Renaissance Technologies LLC now owns 262,160 shares of the company’s stock worth $558,000 after purchasing an additional 169,550 shares during the last quarter. Finally, Wedge Capital Management L L P NC bought a new stake in Veru during the 2nd quarter worth about $394,000. 8.85% of the stock is owned by hedge funds and other institutional investors.
Veru Company Profile
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Further Reading: Support Level